On March 14, 2022 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, reported a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health (Press release, NexImmune, MAR 14, 2022, View Source [SID1234610048]). The collaboration is centered around NexImmune’s artificial antigen presenting cells’ (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. Dr. Jeffrey S. Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center will guide the research and evaluation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"NexImmune is excited to have Dr. Weber and NYU, one of the nation’s leading academic cancer centers, as a partner on this collaboration," said Kristi Jones, Chief Executive Officer of NexImmune. "The AIM technology platform offers a way to explore the expansion of neoantigens not only in melanoma, but a myriad of other cancers. This step will help validate our approach to these novel targets. Collaboration in this field will continue to help us deliver novel and impactful therapies to people suffering with cancer."
"I look forward to working with NexImmune on this important work, with the goal of advancing these technologies and delivering next-generation immunotherapies to patients suffering with cancer," stated Dr. Weber. "NexImmune’s platform has proven it can consistently expand antigen specific T cells for known tumor and viral antigens. This work could help us create T cell products that directly target disease specific neoantigens by utilizing the AIM platform."
Further terms of this evaluation agreement have not been disclosed.